-
Sawai Announces Listing of Five Generic Drugs with Nine Strengths
-
Sawai Group Holdings and ORIX Agree on Conclusion of Transfer Agreement with Kobayashi Kako -Toward Early Establishment of In-house Annual Production Capacity of 20 Billion Tablets or More-
-
Upsher-Smith Launches Three Additional Strengths of Isotretinoin Capsules
-
Upsher-Smith Launches Carbamazepine Extended-Release Tablets, USP
-
Sawai Receives Approvals for Four Generic Drugs with Eight Strengths
-
Upsher-Smith Launches Isotretinoin Capsules
-
Sawai Launches Eight Generic Drugs with 23 Strengths
-
Upsher-Smith and Rafarm Announce Launch of Moxifloxacin Ophthalmic Solution, USP 0.5%
-
Message from the Chairman and Group CEO
This website uses cookies to enhance customer’s convenience to use the site and keep its functions working properly. For more information about using cookies, please refer to "Terms of Use."